Second-Line Docetaxel Benefits Seen For Esophagogastric Cancers
SAN FRANCISCO (IMNG) - Results of a phase III trial support a common clinical practice - giving docetaxel as second-line chemotherapy to patients with advanced adenocarcinomas of the stomach or esophagus...
Source: OncologySTAT Latest News - Category: Cancer & Oncology Source Type: news
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Esophagus Cancer | Gastric (Stomach) Cancer | Taxotere